Notably, a previous study reported that a novel carcinogenic circRNA derived from reverse splicing of the non-small cell lung cancer fusion gene EML4-ALK variant 3b (V3b) could be detected in the plasma of patients carrying the EML4-ALK gene, indicating that circRNA has potential in cancer diagnosis and clinical treatment as a liquid biopsy marker (140). This evidence concerns the gene EML4 and non-small cell lung carcinoma.